Loading
A phase 2 trial of pembrolizumab in colorectal cancer, run by Solstice Oncology, Inc., not yet recruiting.
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer is a phase 2, randomised interventional study registered as NCT07808151 by Solstice Oncology, Inc., with a registry enrolment figure of 100 participants, started 2026-09-30 and due to reach its primary completion in 2029-09-30. Interventions recorded: Pembrolizumab; Porustobart. Conditions listed: Colon Cancer; Microsatellite Stable (MSS) Colon Cancer; Proficient Mismatch Repair (pMMR) Colon Cancer. Primary outcome: Major Pathologic Response (MPR) rate by Blinded Independent Pathologic Review (BIPR). Colorectal eligibility wording from the registry: "Adenocarcinoma of the colon (rectosigmoid considered non-rectal); pMMR/MSS status". Sites: Belgium, Italy, Netherlands, Spain, United Kingdom, United States. United Kingdom sites listed: 5. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Pembrolizumab and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/